Published Date: 01 Apr 2026
European authorities have backed a targeted BRAF/MEK inhibitor combo for radioactive iodine-refractory thyroid cancer and extended its use to adolescents with advanced or resected melanoma.
Read Full NewsEnhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection
Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights
Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death
Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors
"Combinations represent additional options for early-line treatment," researcher says
The bispecific T-cell engager also reduced toxicity in newly diagnosed kids
A combination of clinician and patient prompts worked best, but talks remained infrequent
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation